Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial aims to ease pouch disorder symptoms

NCT ID NCT06864403

First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 32 times

Summary

This study tests if mirikizumab can reduce symptoms like frequent bowel movements and urgency in adults with chronic pouch inflammation. About 25 participants will receive the drug every 4 weeks for a year and track their symptoms. The goal is to see if the treatment helps control the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POUCHITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Allegheny Health Network

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UCLA Vatche & Tamar Manoukian Division of Digestive Diseases

    RECRUITING

    Los Angeles, California, 90024, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of North Carolina

    RECRUITING

    Chapel Hill, North Carolina, 27599-7080, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.